Summary: A propylamine derivative and selective ADRENERGIC UPTAKE INHIBITOR that is used in the treatment of ATTENTION DEFICIT HYPERACTIVITY DISORDER.
Castellanos F, Meyer E. Toward systems neuroscience of shared and distinct neural effects of medications used to treat attention-deficit/hyperactivity disorder. Biol Psychiatry. 2013;74:560-2 pubmed publisher
Clemow D. Suboptimal dosing of Strattera (atomoxetine) for ADHD patients. Postgrad Med. 2014;126:196-8 pubmed
..Atomoxetine dose titration, setting patient expectations, and the importance of keeping the patient at target dose for an adequate length of time (about 4âˆ’6 weeks) prior to judging efficacy are also discussed. ..
Warren C, Wilson R, van der Wee N, Giltay E, van Noorden M, Cohen J, et al
. The effect of atomoxetine on random and directed exploration in humans. PLoS ONE. 2017;12:e0176034 pubmed publisher
Lu Y, Sjölander A, Cederlöf M, D Onofrio B, Almqvist C, Larsson H, et al
. Association Between Medication Use and Performance on Higher Education Entrance Tests in Individuals With Attention-Deficit/Hyperactivity Disorder. JAMA Psychiatry. 2017;74:815-822 pubmed publisher
..These findings suggest that ADHD medications may help ameliorate educationally relevant outcomes in individuals with ADHD. ..
Dittmann R, Cardo E, Nagy P, Anderson C, Bloomfield R, Caballero B, et al
. Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study. CNS Drugs. 2013;27:1081-92 pubmed
..Both treatments displayed safety profiles consistent with findings from previous clinical trials. ..
Volkow N, Swanson J. Clinical practice: Adult attention deficit-hyperactivity disorder. N Engl J Med. 2013;369:1935-44 pubmed publisher
Quinn P, Chang Z, Hur K, Gibbons R, Lahey B, Rickert M, et al
. ADHD Medication and Substance-Related Problems. Am J Psychiatry. 2017;174:877-885 pubmed publisher
..Rather, medication was associated with lower concurrent risk of substance-related events and, at least among men, lower long-term risk of future substance-related events. ..